Denali Therapeutics (DNLI) Operating Leases (2019 - 2025)
Historic Operating Leases for Denali Therapeutics (DNLI) over the last 7 years, with Q3 2025 value amounting to $38.8 million.
- Denali Therapeutics' Operating Leases fell 1713.94% to $38.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year decrease of 1713.94%. This contributed to the annual value of $36.7 million for FY2024, which is 1847.0% down from last year.
- Latest data reveals that Denali Therapeutics reported Operating Leases of $38.8 million as of Q3 2025, which was down 1713.94% from $41.0 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Operating Leases registered a high of $67.8 million during Q1 2021, and its lowest value of $36.7 million during Q4 2024.
- In the last 5 years, Denali Therapeutics' Operating Leases had a median value of $53.9 million in 2023 and averaged $53.4 million.
- Per our database at Business Quant, Denali Therapeutics' Operating Leases plummeted by 489.87% in 2022 and then tumbled by 1847.0% in 2024.
- Over the past 5 years, Denali Therapeutics' Operating Leases (Quarter) stood at $58.6 million in 2021, then dropped by 9.43% to $53.0 million in 2022, then dropped by 15.18% to $45.0 million in 2023, then decreased by 18.47% to $36.7 million in 2024, then increased by 5.94% to $38.8 million in 2025.
- Its last three reported values are $38.8 million in Q3 2025, $41.0 million for Q2 2025, and $43.0 million during Q1 2025.